Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial.
about
Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trialsRisk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsA systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipientsEffect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.Systemic meta-analysis assessing the short term applicability of early conversion to mammalian target of rapamycin inhibitors in kidney transplant.Sirolimus conversion efficacy for graft function improvement and histopathology in renal recipients with mild to moderate renal insufficiency.Deferred pre-emptive switch from calcineurin inhibitor to sirolimus leads to improvement in GFR and expansion of T regulatory cell population: a randomized, controlled trial.Safety of immunosuppressive drugs used as maintenance therapy in kidney transplantation: a systematic review and meta-analysis.Identification and characterization of kidney transplants with good glomerular filtration rate at 1 year but subsequent progressive loss of renal function.An evaluation of sirolimus in renal transplantation.Is it time to give up with calcineurin inhibitors in kidney transplantation?Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients.Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis.Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant.CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis.Practical considerations for the use of mTOR inhibitors.Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study.Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial.An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors.Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term OutcomesFibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcineurin inhibitors.Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study.Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation.Cost-effectiveness of modern mTOR inhibitor based immunosuppression compared to the standard of care after renal transplantation in Germany.Long-term side effects of treatment with mTOR inhibitors in children after renal transplantation.Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients.Sirolimus inhibits lymphangiogenesis in rat renal allografts, a novel mechanism to prevent chronic kidney allograft injury.Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial.Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen.Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial.Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study.Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation.Rapamycin Interferes With Postdepletion Regulatory T Cell Homeostasis and Enhances DSA Formation Corrected by CTLA4-Ig.
P2860
Q26823281-13470E71-FE4F-449F-A497-B014CD711D18Q26851417-BFB34135-5962-4392-AA2C-73382D14DD06Q27000107-28EAFD08-09E8-49BD-9452-66CCEF23E35BQ30871643-FCB74798-5402-42C7-9086-4A3C5EA9C2CFQ33617408-35A783D5-2596-4A47-BBF1-0F999B6B1EC6Q34029931-B3323551-5127-49A1-92BB-105A49FF4771Q35022430-0084DB29-2BDC-4A82-8FD2-E7A93DF0426FQ37280007-216AB638-63C4-41A9-A714-8503FA09CF4DQ37535280-F13934B6-006B-43C2-9B05-040FDD9AA44DQ38038696-6D34BAE5-C14B-4EA7-8922-90EBC35ABF7EQ38156847-5F76405C-D573-40D1-BE5B-7296E4C0E323Q38190678-BD002936-14D9-43D0-9276-64C4B2615074Q38241710-F20C8B3A-52CA-47EB-B450-E582F52BD1D0Q38242068-448A21AC-8DC0-4129-8DE4-31917C46083EQ38668601-E964EB5A-D753-4CF3-ADDD-214632C474CAQ38731333-D43F5DE2-837F-4C8C-A24F-D553F7E0071CQ38747503-89182AB6-73F2-42E1-A886-418B726F35BDQ38779769-A14854FF-7257-41EA-8EA1-0085B2260762Q38863078-64E34E8A-954E-4302-806E-D6F285E28634Q38914374-101CC0B9-EBA1-44DD-8D7F-69FD9BF6595AQ39450656-7FAE73FB-98B8-4F95-BBF5-4AADFAD4CB76Q39757990-0828A27E-0CFD-4901-8C25-7B9A0C01C36AQ40073566-E1E58BE9-F051-4CBC-B034-9DCA1B484AF8Q40176051-DFE70818-345E-4715-9EF9-71D5C69D3459Q40200912-681D5F70-D719-4A9C-9E91-429C270182CCQ40940603-CE72309E-4B9F-4323-9C69-4325A4BBF913Q41313340-0C3FBA1A-4F6E-452B-B623-8610C84026EEQ41631814-8E103F71-72FE-4F68-B8E3-FB124A561B67Q41673673-8D54240F-A514-449A-B678-BE0F7A21A4E0Q42679895-89569593-D753-4143-8520-01E51CEBDFE6Q43529813-3130EC43-513B-49B4-A41D-10D169FA6C7BQ43534252-77F05080-EA98-4B64-A8E4-AFD07744BF8CQ45117076-BD95AF1B-B4D7-4C59-BA51-8ADB1B545D2FQ45883054-83543288-A9EC-4F1E-9E3B-11756CEA0476Q47309233-0AFDB91C-C1DF-4A91-B2EC-66FF265ADF88Q51037981-3091A9B0-FF66-4C17-B138-8FAFB1A937C6Q52874072-BAA25BA3-66EC-4422-ADBA-AEBD212C73C2Q52888129-E3D2DAAB-53F6-4093-BB21-FA7CCA84AB79Q52889823-5AFDD0B1-2653-4C31-AE03-6E557FBB8EF3Q53145957-C5C83901-F24B-424D-8AEF-71A08CABCF95
P2860
Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Renal function, efficacy, and ...... randomized multicenter trial.
@en
Renal function, efficacy, and ...... randomized multicenter trial.
@nl
type
label
Renal function, efficacy, and ...... randomized multicenter trial.
@en
Renal function, efficacy, and ...... randomized multicenter trial.
@nl
prefLabel
Renal function, efficacy, and ...... randomized multicenter trial.
@en
Renal function, efficacy, and ...... randomized multicenter trial.
@nl
P2093
P50
P1433
P1476
Renal function, efficacy, and ...... randomized multicenter trial.
@en
P2093
Andreas Pascher
Bernhard Banas
Bernhard K Krämer
Christian Hugo
Constanze Nohr-Westphal
Jens Brockmann
Joachim Andrassy
Karl-Walter Jauch
Katharina Pressmar
Markus Guba
P304
P356
10.1097/TP.0B013E3181E11798
P577
2010-07-01T00:00:00Z